There is a growing trend among retina specialists to use anti-VEGF therapy over PRP to treat PDR in patients with reliable follow-up and on chronic anti-VEGF therapy for concurrent diabetic macular edema (DME) [33]. This evidence concerns the gene VEGFA and diabetic macular edema.